A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular Carcinoma
Clinical trial NCT06841185 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06841185
- Sponsor
- Shanghai Henlius Biotech
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-30
- Primary completion
- 2027-06-06
- Enrollment
- 656
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.